Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia

Abstract Array comparative genomic hybridization (aCGH) has yet to be fully leveraged in a prognostic setting in chronic lymphocytic leukemia (CLL). Genomic imbalance was assessed in 288 CLL specimens using a targeted array. Based on 20 aberrations in a hierarchical manner, all 228 treatment-naive specimens were classified into a group with poor outcome (20.6%) exhibiting at least one aberration that was univariately associated with adverse outcome (gain: 2p, 3q, 8q, 17q, loss: 7q, 8p, 11q, 17p, 18p), good outcome (32.5%) showing 13q14 loss without any of the other 10 aberrations (gain: 1p, 7p, 12, 18p, 18q, 19, loss: 4p, 5p, 6q, 7p) or intermediate outcome (remainder). The three groups were significantly separated with respect to time to first treatment and overall survival (p < 0.001), and validation of the stratification scheme was performed in two independent datasets. Gain of 3q and 8q, and 17p loss were determined to be independent unfavorable prognostic biomarkers. TP53, NOTCH1 and SF3B1 mutations correlated with the presence of one poor outcome aCGH marker, at a considerably higher frequency than when only considering poor risk aberrations routinely detected by fluorescence in situ hybridization (FISH). These data support genomic imbalance evaluation in CLL by aCGH to assist in risk stratification.

[1]  Alex Sazonovs,et al.  Whole Genome Sequencing , 2020, Definitions.

[2]  T. Stankovic,et al.  The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia , 2014, Leukemia & lymphoma.

[3]  F. Angrilli,et al.  Chromosome 2p gain in monoclonal B‐cell lymphocytosis and in early stage chronic lymphocytic leukemia , 2013, American journal of hematology.

[4]  A. Regev,et al.  Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia , 2012, Clinical Cancer Research.

[5]  U. Klein,et al.  Functional dissection of the chromosome 13q14 tumor-suppressor locus using transgenic mouse lines. , 2012, Blood.

[6]  F. Cavalli,et al.  Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype , 2012, Hematological oncology.

[7]  N. Pochet,et al.  Germline copy number variation associated with Mendelian inheritance of CLL in two families , 2012, Leukemia.

[8]  Y. Pekarsky,et al.  NOTCH1 mutations in CLL associated with trisomy 12. , 2012, Blood.

[9]  L. Pasqualucci,et al.  Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. , 2011, Blood.

[10]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[11]  L. Pasqualucci,et al.  Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. , 2011, Blood.

[12]  S. Pileri,et al.  Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. , 2011, Blood.

[13]  M. Kaminski,et al.  Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. , 2011, Blood.

[14]  P. Ouillette,et al.  The Prognostic Significance of Various 13q14 Deletions in Chronic Lymphocytic Leukemia , 2011, Clinical Cancer Research.

[15]  F. Cavalli,et al.  Genome‐wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia , 2011, British journal of haematology.

[16]  D. Goldenberg,et al.  Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers. , 2011, Blood.

[17]  R. Foà,et al.  13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia , 2011, Genes, chromosomes & cancer.

[18]  Hanna Göransson,et al.  Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia , 2011, Haematologica.

[19]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[20]  L. Pasqualucci,et al.  Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.

[21]  G. Morgan,et al.  Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A Collins,et al.  13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia , 2011, Leukemia.

[23]  David D. Smith,et al.  Evaluation of chronic lymphocytic leukemia by BAC-based microarray analysis , 2011, Molecular Cytogenetics.

[24]  J. Byrd,et al.  Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. , 2010, Cancer genetics and cytogenetics.

[25]  F. Ferrari,et al.  Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion , 2010, Clinical Cancer Research.

[26]  H. Döhner,et al.  TP53 mutation and survival in chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Jeffrey A Jones,et al.  Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease , 2009, British journal of haematology.

[28]  T. Shanafelt,et al.  A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B‐chronic lymphocytic leukaemia , 2010, British journal of haematology.

[29]  B. Lakshmi,et al.  Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). , 2009, Blood.

[30]  Francesco Bertoni,et al.  Genome‐wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion , 2008, British journal of haematology.

[31]  D. de Jong,et al.  Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. , 2008, The Journal of molecular diagnostics : JMD.

[32]  M. Kaminski,et al.  Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. , 2008, Cancer research.

[33]  A. Ashworth,et al.  Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation , 2008, Leukemia & lymphoma.

[34]  M. Kaminski,et al.  Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. , 2007, Blood.

[35]  T. Shanafelt,et al.  Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Veronese,et al.  Chronic lymphocytic leukemia with 6q− shows distinct hematological features and intermediate prognosis , 2004, Leukemia.

[37]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[38]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[39]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[40]  Luca Laurenti,et al.  Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. , 2012, Blood.

[41]  S. Staprans,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on March 1, 2013. For personal use , 2006 .